Immuno-Oncology
IMW 2021: treatment-free intervals in multiple myeloma
Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for…
Date: 29th September 2021
Highlights from iwCLL 2021
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel…
Date: 27th September 2021
CAR-T vs bispecifics: replacing ASCT in myeloma
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;…
Date: 17th September 2021
EHA 2021: antibody therapies for NHL
Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20…
Date: 10th September 2021
EHA 2021: updates on novel agents for AML
A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older…
Date: 8th September 2021
EHA 2021: targeted therapies for ALL
Great progress has been made in the treatment of acute lymphocytic leukemia (ALL), primarily owing to the development of targeted…
Date: 1st September 2021
EHA 2021: real-world data on myeloma, lymphoma and CLL
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…
Date: 25th August 2021
Latest updates on T-cell therapies for non-Hodgkin lymphoma
Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such…
Date: 18th August 2021
Novel CD20/CD3 bispecific antibodies in NHL
Immunotherapies are showing increasingly promising results for the treatment of patients with non-Hodgkin lymphoma (NHL) and, in particular, bispecific antibodies…
Date: 17th August 2021
Latest updates on CAR-T therapy for lymphoma
At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for…
Date: 16th August 2021
EHA & ICML 2021: updates in Hodgkin lymphoma
Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events,…
Date: 6th August 2021
Latest transplant updates from EHA 2021
Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease…
Date: 4th August 2021
